Taking stock of the drug industry, from the lab to the medicine chest

October 30, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

ANDREW YATES/AFP via Getty Images AstraZeneca's China president is under investigation by authorities One Chinese government probe is reportedly related to collection of patient data, and whether that infringed data-privacy laws. By Ed Silverman STAT+ | Eli Lilly hits rare stumble, as sales and earnings disappoint The company's quarterly earnings report comes as it faces off with compounding pharmacies amid questions about shortages of its drug. By Elaine Chen STAT+ | Sales of GSK's RSV vaccine down dramatically from last year A narrower recommendation for who should get the shot from U.S. officials is one reason sales of the shot were down year over year. By Andrew Joseph Adobe STAT+ | Early data from Roche's Alzheimer's therapy show it's hitting targets The company is testing an amyloid-clearing antibody with its Brainshuttle tool, which helps drugs reach into the brain. By Andrew Joseph STAT+ | With $115 million, biotech startup Axonis Therapeutics pivots to burgeoning pain field The Boston-based company has raised a fresh $115 million, will focus on microscopic currents of electrically charged particles moving through ion channels. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser